BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

948 related articles for article (PubMed ID: 24355040)

  • 1. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P;
    J Sex Med; 2014 Mar; 11(3):840-56. PubMed ID: 24308723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial.
    Gianatti EJ; Dupuis P; Hoermann R; Zajac JD; Grossmann M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3821-8. PubMed ID: 24978674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
    Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
    Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
    J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.
    Yassin AA; Saad F
    J Sex Med; 2007 Mar; 4(2):497-501. PubMed ID: 17367445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L; Lazarou S; Morgentaler A
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.